Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy.
Burgard C, Khreish F, Dahlmanns L, Blickle A, Bastian MB, Speicher T, Maus S, Schaefer-Schuler A, Bartholomä M, Petto S, Ezziddin S, Rosar F. Burgard C, et al. Among authors: petto s. Cancers (Basel). 2024 Oct 19;16(20):3532. doi: 10.3390/cancers16203532. Cancers (Basel). 2024. PMID: 39456626 Free PMC article.
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S. Burgard C, et al. Among authors: petto s. Cancer Imaging. 2024 Oct 7;24(1):132. doi: 10.1186/s40644-024-00778-5. Cancer Imaging. 2024. PMID: 39375762 Free PMC article.
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).
Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S, Petto S, Khreish F, Schaefer A, Ezziddin S. Rosar F, et al. Among authors: petto s. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4151-4162. doi: 10.1007/s00259-024-06825-4. Epub 2024 Jul 15. Eur J Nucl Med Mol Imaging. 2024. PMID: 39008067 Free PMC article.
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617.
Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, Bartholomä M, Stemler T, Ezziddin S, Rosar F. Schaefer-Schuler A, et al. Among authors: petto s. Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. eCollection 2024. Theranostics. 2024. PMID: 38505615 Free PMC article.
[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S. Rosar F, et al. Among authors: petto s. Cancer Imaging. 2024 Feb 22;24(1):27. doi: 10.1186/s40644-024-00671-1. Cancer Imaging. 2024. PMID: 38389092 Free PMC article.
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
Burgard C, Hein C, Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. Burgard C, et al. Among authors: petto s. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):885-895. doi: 10.1007/s00259-023-06476-x. Epub 2023 Oct 27. Eur J Nucl Med Mol Imaging. 2024. PMID: 37889298 Free PMC article.
12 results